|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,860.00 KRW | +0.21% |
|
-8.82% | -28.74% |
| 12-09 | GC Genome Study Identifies 'Confounders' Interfering with Cancer Signals to Improve Liquid Biopsy Accuracy | CI |
| 12/06/25 | GC Genome Shares Decline Nearly 3% After Strong Kosdaq Debut | MT |
Company Valuation: GC Genome Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2025 | 2026 | 2027 |
|---|---|---|---|
| Market Cap 1 | 161,298 | 114,943 | - |
| Change | - | -28.74% | - |
| Enterprise Value (EV) 1 | 161.3 | 55.54 | 46.14 |
| Change | - | -65.57% | -16.92% |
| P/E | 36.9x | - | - |
| PBR | - | - | - |
| PEG | -0x | - | - |
| Capitalization / Revenue | - | 2.95x | 2.36x |
| EV / Revenue | - | 1.42x | 0.95x |
| EV / EBITDA | - | - | - |
| EV / EBIT | - | 13.9x | 6.59x |
| EV / FCF | - | - | - |
| FCF Yield | - | - | - |
| Dividend per Share 3 | - | - | - |
| Rate of return | - | - | - |
| EPS 3 | 185 | - | - |
| Distribution rate | - | - | - |
| Net sales 1 | - | 39 | 48.8 |
| EBITDA | - | - | - |
| EBIT 1 | - | 4 | 7 |
| Net income | 4.044 | - | - |
| Net Debt 1 | - | -59.4 | -68.8 |
| Reference price 3 | 6,820.00 | 4,860.00 | 4,860.00 |
| Nbr of stocks (in thousands) | 23,651 | 23,651 | - |
| Announcement Date | 16/3/26 | - | - |
1KRW in Million2KRW in Billions3KRW
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| - | 1.42x | - | - | 74.93M | ||
| -139.71x | 11.48x | -158.84x | -.--% | 33.14B | ||
| 17.77x | 1.74x | 10.03x | 1.14% | 20.98B | ||
| 16.09x | 1.28x | 7.26x | 5.41% | 6.95B | ||
| 275.59x | - | - | - | 4.23B | ||
| 53.92x | 9.52x | 33.43x | 0.86% | 2.9B | ||
| -19.69x | - | - | - | 1.75B | ||
| 33.69x | 1.47x | 11.96x | 1.6% | 1.68B | ||
| 28.61x | 1.15x | 9.52x | 0.88% | 1.65B | ||
| 11.74x | 1.25x | 4.87x | 6.44% | 1.58B | ||
| Average | 30.89x | 3.66x | -11.68x | 2.33% | 7.49B | |
| Weighted average by Cap. | -36.57x | 6.67x | -70.61x | 1.14% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- A340450 Stock
- Valuation GC Genome Corporation
Select your edition
All financial news and data tailored to specific country editions
















